DA
MIRM icon

Denali Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Denali Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,800
Closed -$176K – 514
2023
Q2 		$176K Buy
+6,800
New +$181K 0.06% 227

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Denali Advisors's MIRM Position: Q3 2023 in Review

Denali Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q3 2023, closing a stake of 6,800 shares — an estimated $176K sold.

Denali Advisors first reported a position in MIRM in Q2 2023 and held it in 1 quarter. The position peaked at $176K in Q2 2023. 159 funds tracked by Wall St. Rank hold MIRM as of Q3 2023.

  • Denali Advisors reported no remaining Mirum Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Denali Advisors sold 6,800 Mirum Pharmaceuticals shares in Q3 2023, an estimated $176K.
  • Denali Advisors first reported a position in Mirum Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Denali Advisors's Mirum Pharmaceuticals position peaked at $176K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.